

# Preservatives in eyedrops: The good, the bad and the ugly

Progress in Retinal and Eye Research

29, 312-334

DOI: [10.1016/j.preteyeres.2010.03.001](https://doi.org/10.1016/j.preteyeres.2010.03.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Preserved and Unpreserved 12 Anti-allergic Ophthalmic Solutions and Ocular Surface Toxicity: In Vitro Assessment in Four Cultured Corneal and Conjunctival Epithelial Cell Lines. <i>Biocontrol Science</i> , 2010, 15, 143-148.	0.2	14
2	Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells. <i>Clinical Ophthalmology</i> , 2010, 4, 1217.	0.9	39
5	Taflopust for glaucoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2393-2401.	0.9	15
9	Ophthalmic preservatives: focus on polyquaternium-1. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 1425-1438.	2.4	25
10	Comparative <i>In Vitro</i> Toxicology Study of Travoprost Polyquad-preserved, Travoprost BAK-preserved, and Latanoprost BAK-preserved Ophthalmic Solutions on Human Conjunctival Epithelial Cells. <i>Current Eye Research</i> , 2011, 36, 979-988.	0.7	29
11	<i>In Vitro</i> Comparative Toxicology of Polyquad-Preserved and Benzalkonium Chloride-Preserved Travoprost/Timolol Fixed Combination and Latanoprost/Timolol Fixed Combination. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 273-280.	0.6	32
12	Ocular Surface Disease in Patients with Ocular Hypertension and Glaucoma. <i>Current Eye Research</i> , 2011, 36, 391-398.	0.7	95
14	Spectrofluorometry assays for oxidative stress and apoptosis, with cell viability on the same microplates: A multiparametric analysis and quality control. <i>Toxicology in Vitro</i> , 2011, 25, 1089-1096.	1.1	11
15	Antiglaucoma drugs: The role of preservative-free formulations. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 389-394.	0.3	15
16	Preservative Use in Topical Glaucoma Medications. <i>Ocular Surface</i> , 2011, 9, 140-158.	2.2	37
17	Challenges in the clinical measurement of ocular surface disease in glaucoma patients. <i>Clinical Ophthalmology</i> , 2011, 5, 1575.	0.9	29
18	The Use of Mucoadhesive Polymers to Enhance the Hypotensive Effect of a Melatonin Analogue, 5-MCA-NAT, in Rabbit Eyes. , 2011, 52, 1507.		21
19	Surface Chemistry Study of the Interactions of Benzalkonium Chloride with Films of Meibum, Corneal Cells Lipids, and Whole Tears. , 2011, 52, 4645.		43
20	Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive Polymers. , 2011, 52, 3548.		28
21	Impact of Multipurpose Solutions Released from Contact Lenses on Corneal Cells. <i>Optometry and Vision Science</i> , 2011, 88, 483-492.	0.6	24
23	Ocular surface damage by ophthalmic compounds. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 464-470.	1.1	35
24	A Practical Treatment Algorithm for Managing Ocular Surface and Tear Disorders. <i>Cornea</i> , 2011, 30, S8-S14.	0.9	20
25	In Vitro Assessment of the Cytotoxicity of Anti-allergic Eye Drops Using 5 Cultured Corneal and Conjunctival Cell Lines. <i>Journal of Oleo Science</i> , 2011, 60, 139-144.	0.6	13

#	ARTICLE	IF	CITATIONS
26	Cell Viability of Four Corneoconjunctival Cell Lines Exposed to Five Preservatives and a Surfactant Used for Infection Control in Eye Drops. <i>Biocontrol Science</i> , 2011, 16, 117-121.	0.2	11
27	Role of benzalkonium chloride in DNA strand breaks in human corneal epithelial cells. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1681-1687.	1.0	30
28	Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cells. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 541-546.	0.9	20
29	Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. <i>Advances in Therapy</i> , 2011, 28, 311-325.	1.3	40
30	Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. <i>Advances in Therapy</i> , 2011, 28, 575-585.	1.3	26
31	Ocular Surface Epithelial Thickness Evaluation with Spectral-Domain Optical Coherence Tomography. , 2011, 52, 9116.		120
32	Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. <i>British Journal of Ophthalmology</i> , 2011, 95, 869-875.	2.1	75
33	Symptoms and Signs of Tear Film Dysfunction in Glaucomatous Patients. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 281-285.	0.6	36
34	Current and emerging medical therapies in the treatment of glaucoma. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 293-307.	1.0	31
35	Toxicity Evaluation of Antiglaucoma Drugs Using Stratified Human Cultivated Corneal Epithelial Sheets. , 2012, 53, 5154.		53
36	Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 519-525.	1.0	11
37	Ocular Surface and External Filtration Surgery: Mutual Relationships. <i>Developments in Ophthalmology</i> , 2012, 50, 64-78.	0.1	29
38	Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?. <i>Eye</i> , 2012, 26, 734-741.	1.1	16
39	A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost) and a BAK-Preserved Latanoprost Solution in Animal Models. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 515-523.	0.6	37
40	Reduced in vivo Ocular Surface Toxicity with Polyquad-Preserved Travoprost versus Benzalkonium-Preserved Travoprost or Latanoprost Ophthalmic Solutions. <i>Ophthalmic Research</i> , 2012, 48, 89-101.	1.0	49
41	Corneal Neurotoxicity Due to Topical Benzalkonium Chloride. , 2012, 53, 1792.		126
42	Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma. <i>European Journal of Ophthalmology</i> , 2012, 22, 34-44.	0.7	44
43	Efficacy and Tolerability of Prostaglandin-Timolol Fixed Combinations: A Meta-Analysis of Randomized Clinical Trials. <i>European Journal of Ophthalmology</i> , 2012, 22, 5-18.	0.7	62

#	ARTICLE	IF	CITATIONS
44	In Vitro and In Vivo Evaluation of a Preservative-Free Cationic Emulsion of Latanoprost in Corneal Wound Healing Models. <i>Cornea</i> , 2012, 31, 1319-1329.	0.9	31
45	Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension. <i>Cornea</i> , 2012, 31, 994-999.	0.9	66
46	Comparative Study of In Vitro Ocular Surface Cytotoxicity of a Fixed Combination of 0.5% Timolol/1% Dorzolamide Eyedrop and Its Components with 0.005% Benzalkonium Chloride. <i>Biocontrol Science</i> , 2012, 17, 115-120.	0.2	6
47	Cell Viability Score as an Integrated Indicator for Cytotoxicity of Benzalkonium Chloride-Containing Antiglaucoma Eyedrops. <i>Biocontrol Science</i> , 2012, 17, 121-128.	0.2	17
49	Surface Chemistry Study of the Interactions of Pharmaceutical Ingredients with Human Meibum Films. , 2012, 53, 4605.		28
50	CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation. <i>Mucosal Immunology</i> , 2012, 5, 702-711.	2.7	20
54	The Corneal Pain System. Part I: The Missing Piece of the Dry Eye Puzzle. <i>Ocular Surface</i> , 2012, 10, 2-14.	2.2	159
56	Differential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucoma. <i>Molecular BioSystems</i> , 2012, 8, 1017-1028.	2.9	67
57	High molecular weight hyaluronan decreases oxidative DNA damage induced by EDTA in human corneal epithelial cells. <i>Eye</i> , 2012, 26, 1012-1020.	1.1	31
58	Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues. <i>Drugs</i> , 2012, 72, 1355-1371.	4.9	25
59	Use of Microbicides in Disinfection of Contact Lenses. , 0, , 530-536.		0
60	Transport and interaction of cosmetic product material within the ocular surface: Beauty and the beastly symptoms of toxic tears. <i>Contact Lens and Anterior Eye</i> , 2012, 35, 247-259.	0.8	41
61	Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems. <i>Pharmaceutics</i> , 2012, 4, 252-275.	2.0	67
62	Corneal Epithelial Cell Viability Following Exposure to Ophthalmic Solutions Containing Preservatives and/or Antihypertensive Agents. <i>Advances in Therapy</i> , 2012, 29, 874-888.	1.3	20
63	Research on the Stability of a Rabbit Dry Eye Model Induced by Topical Application of the Preservative Benzalkonium Chloride. <i>PLoS ONE</i> , 2012, 7, e33688.	1.1	57
64	A New Safety Concern for Glaucoma Treatment Demonstrated by Mass Spectrometry Imaging of Benzalkonium Chloride Distribution in the Eye, an Experimental Study in Rabbits. <i>PLoS ONE</i> , 2012, 7, e50180.	1.1	92
65	The Role of Medications in Causing Dry Eye. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-8.	0.6	87
66	Therapeutic Effects of Epidermal Growth Factor on Benzalkonium Chloride-Induced Dry Eye in a Mouse Model. , 2012, 53, 191.		52

#	ARTICLE	IF	CITATIONS
67	In Vitro and In Vivo Comparative Toxicological Study of a New Preservative-Free Latanoprost Formulation. , 2012, 53, 8172.		39
68	Conjunctival inflammation in patients under topical glaucoma treatment with indication to surgery. Acta Cirurgica Brasileira, 2012, 27, 732-735.	0.3	6
69	In Vitro Interactions between Peripheral Blood Lymphocytes and the Wong-Kilbourne Derivative of Chang Conjunctival Cells. , 2012, 53, 1492.		0
70	A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clinical Ophthalmology, 2012, 6, 441.	0.9	67
71	Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmologica, 2012, 90, e221-4.	0.6	52
72	Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease. Progress in Retinal and Eye Research, 2012, 31, 271-285.	7.3	256
73	Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Australasian journal of optometry, The, 2012, 95, 198-206.	0.6	44
74	Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 4039-4049.	1.9	47
75	Shotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naïve to therapy. Molecular BioSystems, 2013, 9, 1108.	2.9	79
76	Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 817-824.	1.0	9
77	Ocular Surface Tolerability of Prostaglandin Analogs and Prostaglandin Derivatives in Patients with Glaucoma or Ocular Hypertension. Advances in Therapy, 2013, 30, 260-270.	1.3	27
78	Allethrin toxicity on human corneal epithelial cells involves mitochondrial pathway mediated apoptosis. Toxicology in Vitro, 2013, 27, 2242-2248.	1.1	25
79	Flexible probe for in vivo quantification of corneal epithelium permeability through non-invasive tetrapolar impedance measurements. Biomedical Microdevices, 2013, 15, 849-858.	1.4	5
80	Surface chemistry study of the interactions of hyaluronic acid and benzalkonium chloride with meibomian and corneal cell lipids. Soft Matter, 2013, 9, 10841.	1.2	23
81	Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2013, 14, 1815-1827.	0.9	11
82	Exposure study to examine chemosensory effects of formaldehyde on hyposensitive and hypersensitive males. International Archives of Occupational and Environmental Health, 2013, 86, 107-117.	1.1	29
83	Aclaramiento lagrimal y sintomatología ocular en pacientes tratados con prostaglandinas sin conservantes. Archivos De La Sociedad Espanola De Oftalmologia, 2013, 88, 88-91.	0.1	5
84	Amniotic membrane extract ameliorates benzalkonium chloride-induced dry eye in a murine model. Experimental Eye Research, 2013, 115, 31-40.	1.2	33

#	ARTICLE	IF	CITATIONS
85	Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. Archivos De La Sociedad Espanola De Oftalmologia, 2013, 88, 88-91.	0.1	4
86	Cell viability score (CVS) as a good indicator of critical concentration of benzalkonium chloride for toxicity in cultured ocular surface cell lines. Regulatory Toxicology and Pharmacology, 2013, 66, 177-183.	1.3	39
87	Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance. Journal Francais D'Ophthalmologie, 2013, 36, 316-323.	0.2	6
88	A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye. Ophthalmology, 2013, 120, 1158-1165.	2.5	105
89	Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Current Opinion in Pharmacology, 2013, 13, 56-64.	1.7	56
90	Antifungal effect of ophthalmic preservatives phenylmercuric nitrate and benzalkonium chloride on ocular pathogenic filamentous fungi. Diagnostic Microbiology and Infectious Disease, 2013, 75, 64-67.	0.8	16
91	Autologous serum eye drops for dry eye. , 2013, , CD009327.		89
92	Comparison of the Effects of Ophthalmic Solutions on Human Corneal Epithelial Cells Using Fluorescent Dyes. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 794-802.	0.6	25
93	Emerging treatments for dry eye: Some like it hot, while others may prefer a good stimulation. British Journal of Ophthalmology, 2013, 97, 539-540.	2.1	1
94	Benzalkonium chloride breaks down conjunctival immunological tolerance in a murine model. Mucosal Immunology, 2013, 6, 24-34.	2.7	33
95	Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology, 2013, 97, 196-200.	2.1	82
96	Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. British Journal of Ophthalmology, 2013, 97, 989-993.	2.1	38
97	In vivo confocal microscopy of meibomian glands in glaucoma. British Journal of Ophthalmology, 2013, 97, 343-349.	2.1	62
98	Changes in Rabbit Corneal Innervation Induced by the Topical Application of Benzalkonium Chloride. Cornea, 2013, 32, 1599-1606.	0.9	26
99	Glaucoma therapy and ocular surface disease. Current Opinion in Ophthalmology, 2013, 24, 136-143.	1.3	85
100	Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. British Journal of Ophthalmology, 2013, 97, 1510-1515.	2.1	60
101	Preservative Exposure and Surgical Outcomes in Glaucoma Patients. Journal of Glaucoma, 2013, 22, 730-735.	0.8	115
102	The Impact of Silicone Hydrogel Solution Combinations on Corneal Epithelial Cells. Eye and Contact Lens, 2013, 39, 42-47.	0.8	10

#	ARTICLE	IF	CITATIONS
103	Imaging the Intact Mouse Cornea Using Coherent Anti-Stokes Raman scattering (CARS). , 2013, 54, 5258.		11
104	Sodium Hyaluronate Decreases Ocular Surface Toxicity Induced by Benzalkonium Chlorideâ€œPreserved Latanoprost: An In Vivo Study. , 2013, 54, 3385.		28
105	An algorithm for the management of allergic conjunctivitis. Allergy and Asthma Proceedings, 2013, 34, 408-420.	1.0	52
106	Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clinical Ophthalmology, 2013, 7, 2131.	0.9	68
107	Conjunctival goblet cells density and preservativeâ€œfree tafluprost therapy for glaucoma: an <i>in vivo</i> confocal microscopy and impression cytology study. Acta Ophthalmologica, 2013, 91, e397-405.	0.6	49
108	How Ocular Surface Disease Impacts the Glaucoma Treatment Outcome. BioMed Research International, 2013, 2013, 1-7.	0.9	57
109	Are preservatives necessary to improve efficacy of some glaucoma drops?. British Journal of Ophthalmology, 2013, 97, 1493-1494.	2.1	3
110	Effect of Preservative-Free Tafluprost on Keratocytes, Sub-Basal Nerves, and Endothelium: A Single-Blind One-Year Confocal Study on Na <sup>+</sup> ve or Treated Glaucoma and Hypertensive Patients Versus a Control Group. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 821-825.	0.6	20
111	Risk Factors to Develop Ocular Surface Disease in Treated Glaucoma or Ocular Hypertension Patients. European Journal of Ophthalmology, 2013, 23, 296-302.	0.7	83
112	Preservative-free Treatment in Glaucoma: Who, when, and why?. European Journal of Ophthalmology, 2013, 23, 518-525.	0.7	38
113	Comparative Study of Central Corneal Thickness Using Fourier-Domain Optical Coherence Tomography Versus Ultrasound Pachymetry in Primary Open-Angle Glaucoma. Cornea, 2013, 32, 9-13.	0.9	15
115	<i>In Vitro</i> Effects of Preservative-free and Preserved Prostaglandin Analogs on Primary Cultured Human Conjunctival Fibroblast Cells. Korean Journal of Ophthalmology: KJO, 2013, 27, 446.	0.5	16
116	The need for artificial tears in glaucoma patients: a comparative, retrospective study. Arquivos Brasileiros De Oftalmologia, 2013, 76, 6-9.	0.2	5
117	The TFOS International Workshop on Contact Lens Discomfort: Report of the Management and Therapy Subcommittee. , 2013, 54, TFOS183.		61
118	The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension. Arquivos Brasileiros De Oftalmologia, 2013, 76, 221-225.	0.2	8
119	Ocular Inflammation and Corneal Permeability Alteration by Benzalkonium Chloride in Rats: A Protective Effect of a Myosin Light Chain Kinase Inhibitor. , 2013, 54, 2705.		20
120	Assessment of dry eye signs and symptoms and ocular tolerance of a preservative-free lacrimal substitute (Hylabak&reg;) versus a preserved lacrimal substitute (Systane&reg;) used for 3 months in patients after LASIK. Clinical Ophthalmology, 2013, 7, 2289.	0.9	10
121	Tear Fluid Extracellular DNA: Diagnostic and Therapeutic Implications in Dry Eye Disease. , 2013, 54, 8051.		37

#	ARTICLE	IF	CITATIONS
122	Prevalence and Risk Factors for Ocular Surface Disease among Patients Treated over the Long Term for Glaucoma or Ocular Hypertension. <i>European Journal of Ophthalmology</i> , 2013, 23, 47-54.	0.7	79
123	Toxic Keratoconjunctivitis. , 2013, , 189-193.		2
124	The Effects of Topical Carbonic Anhydrase Inhibitors on Nitric Oxide Production in Trabecular Meshwork Cells. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 416.	0.0	0
125	Benzalkonium Chloride Suppresses Rabbit Corneal Endothelium Intercellular Gap Junction Communication. <i>PLoS ONE</i> , 2014, 9, e109708.	1.1	7
126	Aging: A Predisposition to Dry Eyes. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-8.	0.6	72
127	The Effects of Topical Antiglaucoma Drugs as Monotherapy on the Ocular Surface: A Prospective Study. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-8.	0.6	38
128	Prevalence of Ocular Surface Disease in Patients with Glaucoma using Topical Antiglaucoma Medications. <i>Journal of Clinical &amp; Experimental Ophthalmology</i> , 2014, 05, .	0.1	5
129	Ocular Surface Alterations and Topical Antiglucomatous Therapy: A Review. <i>Open Ophthalmology Journal</i> , 2014, 8, 67-72.	0.1	42
131	Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1737-1747.	0.9	85
132	Benzalkonium Chloride Induces Subconjunctival Fibrosis Through the COX-2-Modulated Activation of a TGF- $\beta$ 1/Smad3 Signaling Pathway. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 8111-8122.	3.3	19
134	Exposure to common quaternary ammonium disinfectants decreases fertility in mice. <i>Reproductive Toxicology</i> , 2014, 50, 163-170.	1.3	92
135	Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren's syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 905-913.	1.5	18
136	Cytoprotective Effect of Lacritin on Human Corneal Epithelial Cells Exposed to Benzalkonium Chloride <i>In Vitro</i>. <i>Current Eye Research</i> , 2014, 39, 604-610.	0.7	12
137	Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2255-2262.	0.9	11
138	Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 531-541.	1.2	97
139	Dry eye disease in French elderly subjects: the Alienor Study. <i>Acta Ophthalmologica</i> , 2014, 92, e429-36.	0.6	72
140	Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule. <i>Experimental Eye Research</i> , 2014, 128, 170-180.	1.2	10
141	Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension. <i>Advances in Therapy</i> , 2014, 31, 1213-1227.	1.3	35



#	ARTICLE	IF	CITATIONS
142	<i>In Vivo</i> Laser Scanning Confocal Microscopy of the Ocular Surface in Glaucoma. Microscopy and Microanalysis, 2014, 20, 879-894.	0.2	45
143	Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination. Ophthalmologica, 2014, 231, 166-171.	1.0	18
144	Changes in the Morphological and Functional Patterns of the Ocular Surface in Patients Treated with Prostaglandin Analogues after the Use of TSP 0.5%® Preservative-Free Eyedrops: A Prospective, Multicenter Study. Ophthalmic Research, 2014, 51, 146-152.	1.0	17
145	<i>In vivo</i> confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmologica, 2014, 92, e133-40.	0.6	35
146	A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide (OPC-12759) Ophthalmic Suspension in Patients With Dry Eye. American Journal of Ophthalmology, 2014, 157, 576-583.e1.	1.7	53
147	Why Aren't There More Pharmacotherapies for Dry Eye?. Ocular Surface, 2014, 12, 227-230.	2.2	13
148	A temperature-induced and shear-reversible assembly of latanoprost-loaded amphiphilic chitosan colloids: Characterization and in vivo glaucoma treatment. Acta Biomaterialia, 2014, 10, 3188-3196.	4.1	30
149	Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. British Journal of Ophthalmology, 2014, 98, 926-931.	2.1	37
150	Development of a Cationic Nanoemulsion Platform (Novasorb®) for Ocular Delivery. , 2014, , 517-535.		0
152	A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects. Contact Lens and Anterior Eye, 2014, 37, 106-110.	0.8	17
153	Effects of Benzalkonium Chloride on the Blood-Aqueous and Blood-Retinal Barriers of Pseudophakic Eyes. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 413-418.	0.6	11
154	Difluprednate 0.05% Versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: A Phase III, Multicenter, Randomized Study. , 2014, 55, 2993.		59
155	Prolonged Exposure to Loteprednol Etabonate in Human Tear Fluid and Rabbit Ocular Tissues Following Topical Ocular Administration of Lotemax Gel, 0.5%. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 66-73.	0.6	10
156	Benzalkonium Chloride and Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 163-169.	0.6	68
157	Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. Investigative Ophthalmology and Visual Science, 2014, 55, 7839-7847.	3.3	42
159	Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 548-553.	0.6	19
161	The Effect of Preservatives and Antiglaucoma Treatments on the Ocular Surface of Mice With Dry Eye. , 2014, 55, 6499.		28
162	Restoring Conjunctival Tolerance by Topical Nuclear Factor-ÎB Inhibitors Reduces Preservative-Facilitated Allergic Conjunctivitis in Mice. , 2014, 55, 6116.		32

#	ARTICLE	IF	CITATIONS
163	<i>In Vitro</i> Effects of Preserved and Unpreserved Anti-Allergic Drugs on Human Corneal Epithelial Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 790-798.	0.6	27
165	Design and Development of an In Vitro Tear Replenishment System. <i>Annals of Biomedical Engineering</i> , 2014, 42, 1923-1931.	1.3	8
166	24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost. <i>Advances in Therapy</i> , 2014, 31, 592-603.	1.3	19
167	Preservative-Free Latanoprost Eye Drops in Patients with Primary Open-Angle Glaucoma/Ocular Hypertension. <i>Clinical Drug Investigation</i> , 2014, 34, 521-528.	1.1	22
168	Effect of acacia honey on cultured rabbit corneal keratocytes. <i>BMC Cell Biology</i> , 2014, 15, 19.	3.0	12
169	Topical ophthalmic agents as allergens in periorbital dermatitis. <i>British Journal of Ophthalmology</i> , 2014, 98, 259-262.	2.1	26
170	Analysis of additives in dairy products by liquid chromatography coupled to quadrupole-orbitrap mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1336, 67-75.	1.8	28
171	Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. <i>Acta Biomaterialia</i> , 2014, 10, 4360-4366.	4.1	89
172	Use of preservative-free hyaluronic acid (Hylabak®) for a range of patients with dry eye syndrome: experience in Russia. <i>Clinical Ophthalmology</i> , 2014, 8, 1169.	0.9	16
173	Managing exposure to cleaning products in cats and dogs. <i>The Veterinary Nurse</i> , 2014, 5, 582-587.	0.0	0
174	Stromal opacity secondary to preservative in dilating drops – A case report and review of literature. <i>Journal of Acute Disease</i> , 2014, 3, 77-79.	0.0	1
175	Cysteamine eye drops in the treatment of cystinosis – an Australian perspective. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 440-445.	0.5	6
176	Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis. <i>Journal of Glaucoma</i> , 2015, 24, e145-e150.	0.8	13
177	<i>In Vivo</i> Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study. <i>Korean Journal of Ophthalmology: KJO</i> , 2015, 29, 270.	0.5	33
178	Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients. <i>Clinical Ophthalmology</i> , 2015, 9, 1605.	0.9	6
179	Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timolol. <i>Korean Journal of Ophthalmology: KJO</i> , 2015, 29, 344.	0.5	13
180	Corneoscleral Limbus in Glaucoma Patients: In Vivo Confocal Microscopy and Immunocytological Study. <i>Investigative Ophthalmology and Visual Science</i> , 2015, 56, 2050.		37
181	Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications. <i>Chinese Medical Journal</i> , 2015, 128, 2444-2449.	0.9	19

#	ARTICLE	IF	CITATIONS
182	Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. <i>Clinical Ophthalmology</i> , 2015, 9, 825.	0.9	9
183	Patient satisfaction with glaucoma therapy: reality&nbsp;or myth?. <i>Clinical Ophthalmology</i> , 2015, 9, 785.	0.9	57
184	A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 595.	0.9	30
185	Lacrimal osmolaritu and ocular surface in experimental model of dry eye caused by toxicity. <i>Revista Brasileira De Oftalmologia</i> , 2015, 74, 68-72.	0.1	16
186	Global Consensus on Keratoconus and Ectatic Diseases. <i>Cornea</i> , 2015, 34, 359-369.	0.9	730
187	A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients. <i>Advances in Therapy</i> , 2015, 32, 356-369.	1.3	28
188	The Definition and Classification of Dry Eye Disease. <i>Essentials in Ophthalmology</i> , 2015, , 1-19.	0.0	15
190	Mydriatic insert and intracameral injections compared with mydriatic eyedrops in cataract surgery: Controlled studies. <i>Journal of Cataract and Refractive Surgery</i> , 2015, 41, 1503-1519.	0.7	22
191	Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments. <i>Current Eye Research</i> , 2015, 40, 40-47.	0.7	7
192	Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients â€“ A randomized, double-blind, placebo-controlled study. <i>Journal of Ginseng Research</i> , 2015, 39, 7-13.	3.0	18
193	Pharmacotherapy of Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 63-77.	0.6	121
194	Meibomian Gland Alteration in Patients with Primary Chronic Dacryocystitis: An<i>In vivo</i>Confocal Microscopy Study. <i>Current Eye Research</i> , 2015, 40, 772-779.	0.7	5
195	Novel Potential Treatment Modalities for Ocular Hypertension: Focus on Angiotensin and Bradykinin System Axes. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 131-145.	0.6	13
196	Benzalkonium chloride exposure in cats: a retrospective analysis of 245 cases reported to the Veterinary Poisons Information Service (VPIS). <i>Veterinary Record</i> , 2015, 176, 229-229.	0.2	8
197	Cataract Following Trabeculectomy. , 2015, , 882-888.		0
198	Light aversion and corneal mechanical sensitivity are altered by intrinsically photosensitive retinal ganglion cells in a mouse model ofÂcorneal surface damage. <i>Experimental Eye Research</i> , 2015, 137, 57-62.	1.2	30
199	Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment. <i>Journal of Controlled Release</i> , 2015, 214, 1-11.	4.8	29
200	Therapeutic contact lenses: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1117-1129.	2.4	49

#	ARTICLE	IF	CITATIONS
201	Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015, 31, 156-164.	0.6	20
202	Thrombospondin-1 induces differential response in human corneal and conjunctival epithelial cells lines under in vitro inflammatory and apoptotic conditions. <i>Experimental Eye Research</i> , 2015, 134, 1-14.	1.2	13
203	Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma. <i>Clinical Ophthalmology</i> , 2015, 9, 625.	0.9	34
204	The effects of acacia honey on in vitro corneal abrasion wound healing model. <i>BMC Cell Biology</i> , 2015, 16, 2.	3.0	17
205	From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 619-623.	1.0	15
206	Acid-sensing ion channels detect moderate acidifications to induce ocular pain. <i>Pain</i> , 2015, 156, 483-495.	2.0	47
207	Brimonidine Allergy Presenting as Vernal-like Keratoconjunctivitis. <i>Journal of Glaucoma</i> , 2015, 24, 89-91.	0.8	16
208	Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 609-617.	1.0	18
209	Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension. <i>Drugs</i> , 2015, 75, 1807-1813.	4.9	20
210	Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 97, 30-38.	2.0	4
211	Acute corneal toxicity of latanoprost with different preservatives. <i>Cutaneous and Ocular Toxicology</i> , 2016, 35, 1-6.	0.5	9
212	Biomedical studies by TOF-SIMS imaging. <i>Biointerphases</i> , 2015, 10, 018901.	0.6	20
213	<i>Eye.</i> , 2015, , 163-188.		5
214	A novel in vivo corneal trans-epithelial electrical resistance measurement device. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 76, 65-71.	0.3	9
215	Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. <i>Clinical and Experimental Ophthalmology</i> , 2015, 43, 164-172.	1.3	22
216	Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose&ndash;response phenomenon. <i>Clinical Ophthalmology</i> , 2016, 10, 373.	0.9	5
217	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1759-1765.	0.9	8
218	In Vivo Goblet Cell Density as a Potential Indicator of Glaucoma Filtration Surgery Outcome. , 2016, 57, 2928.		25

#	ARTICLE	IF	CITATIONS
219	Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies. <i>Journal of Clinical &amp; Experimental Ophthalmology</i> , 2016, 07, .	0.1	31
220	Evaluation of Changes in Tear Film Lipid Layer Thickness Using Ocular Surface Interferometer after Artificial Tear Application. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 1857.	0.0	0
221	Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2085-2091.	0.9	13
222	In Vivo Distribution of Corneal Epithelial Dendritic Cells in Patients With Glaucoma. , 2016, 57, 5996.		43
223	Citicoline: A Food Beneficial for Patients Suffering from or Threatened with Glaucoma. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 73.	1.7	20
224	Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. <i>PLoS ONE</i> , 2016, 11, e0158797.	1.1	7
225	Differences in Central Corneal Thickness between Spectral Domain-Optical Coherence Tomography and Ultrasound Pachymetry in Patients with Dry Eye Disease. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-7.	0.6	4
226	The Ocular Surface in Medically Controlled Glaucoma: An In Vivo Confocal Study. , 2016, 57, 1003.		37
227	Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. <i>International Journal of Clinical Practice</i> , 2016, 70, 577-586.	0.8	6
228	Vitamin A Palmitate and Carbomer Gel Protects the Conjunctiva of Patients With Long-term Prostaglandin Analogs Application. <i>Journal of Glaucoma</i> , 2016, 25, 487-492.	0.8	21
229	Evaluation of Blebs After Filtering Surgery With En-Face Anterior-Segment Optical Coherence Tomography: A Pilot Study. <i>Journal of Glaucoma</i> , 2016, 25, e550-e558.	0.8	23
230	Depressed visual field and mood are associated with sleep disorder in glaucoma patients. <i>Scientific Reports</i> , 2016, 6, 25699.	1.6	32
231	Special considerations for glaucoma management in the elderly. <i>Expert Review of Ophthalmology</i> , 2016, 11, 181-189.	0.3	0
232	Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops. <i>Current Eye Research</i> , 2016, 41, 1326-1330.	0.7	3
233	Comparison of the Efficacy of Fluorometholone With and Without Benzalkonium Chloride in Ocular Surface Disease. <i>Cornea</i> , 2016, 35, 234-242.	0.9	27
234	Over the counter (OTC) artificial tear drops for dry eye syndrome. <i>The Cochrane Library</i> , 2016, 2016, CD009729.	1.5	94
235	Oculoplastic considerations in patients withÂglaucoma. <i>Survey of Ophthalmology</i> , 2016, 61, 718-725.	1.7	18
236	Quality of Life in Glaucoma: A Review of the Literature. <i>Advances in Therapy</i> , 2016, 33, 959-981.	1.3	167

#	ARTICLE	IF	CITATIONS
237	Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1271-1283.	0.9	17
238	Novel plasminogen and hyaluronate sodium eye drop formulation for a patient with ligneous conjunctivitis. American Journal of Health-System Pharmacy, 2016, 73, 556-561.	0.5	5
239	Effect of a Matrix Therapy Agent on Corneal Epithelial Healing After Standard Collagen Cross-linking in Patients With Keratoconus. JAMA Ophthalmology, 2016, 134, 1169.	1.4	24
240	Acute Corneal Toxicity of Diquas. Pharmacology, 2016, 98, 56-61.	0.9	1
241	Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1279-1289.	1.5	71
243	Mechanisms and management of dry eye in cataract surgery patients. Current Opinion in Ophthalmology, 2016, 27, 24-30.	1.3	78
244	Pharmacology of Ocular Therapeutics. , 2016, , .		6
245	Ocular pharmacology. Journal of Clinical Pharmacology, 2016, 56, 517-527.	1.0	34
246	Treatment of Dry Eye Disease. The Consultant Pharmacist, 2016, 31, 96-106.	0.4	55
247	Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 109-118.	0.6	30
248	Less Invasive Corneal Transepithelial Electrical Resistance Measurement Method. Ocular Surface, 2016, 14, 37-42.	2.2	9
249	Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Clinical Pharmacokinetics, 2016, 55, 485-494.	1.6	16
250	Identification of Environmental Quaternary Ammonium Compounds as Direct Inhibitors of Cholesterol Biosynthesis. Toxicological Sciences, 2016, 151, 261-270.	1.4	36
252	Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient. Journal Francais D'Ophthalmologie, 2016, 39, 156-163.	0.2	1
253	Preservatives for Topical Ocular Drug Formulations. , 2016, , 419-430.		0
254	Preparation and <i>in vitro</i> / <i>in vivo</i> evaluation of antimicrobial ocular <i>in situ</i> gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. Pharmaceutical Development and Technology, 2016, 21, 600-610.	1.1	23
255	Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy and Asthma Proceedings, 2017, 38, 16-27.	1.0	18
256	Risks from detergent exposure. Companion Animal, 2017, 22, 93-97.	0.0	1

#	ARTICLE	IF	CITATIONS
257	Mucosal immune tolerance at the ocular surface in health and disease. <i>Immunology</i> , 2017, 150, 397-407.	2.0	53
258	The physical properties of generic latanoprost ophthalmic solutions are not identical. <i>Acta Ophthalmologica</i> , 2017, 95, 370-373.	0.6	16
259	Autologous serum eye drops for dry eye. <i>The Cochrane Library</i> , 2017, 2017, CD009327.	1.5	75
260	The Conjunctiva-Associated Lymphoid Tissue in Chronic Ocular Surface Diseases. <i>Microscopy and Microanalysis</i> , 2017, 23, 697-707.	0.2	31
261	Ocular Surface and External Filtration Surgery: Mutual Relationships. <i>Developments in Ophthalmology</i> , 2017, 59, 67-79.	0.1	38
262	24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. <i>Advances in Therapy</i> , 2017, 34, 221-235.	1.3	25
263	Efficacy of benzalkonium chloride against bioluminescent <i>P. aeruginosa</i> ATCC9027 constructs. <i>Biosensors and Bioelectronics</i> , 2017, 97, 8-15.	5.3	2
264	Diplopia and Symblepharon Following Mueller's Muscle Conjunctival Resection in Patients on Long-Term Multiple Antiglaucoma Medications. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2017, 33, S79-S82.	0.4	8
265	Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. <i>Ocular Surface</i> , 2017, 15, 723-729.	2.2	32
266	A Randomized, Controlled Study of the Efficacy and Safety of a New Eyedrop Formulation for Moderate to Severe Dry Eye Syndrome. <i>European Journal of Ophthalmology</i> , 2017, 27, 1-9.	0.7	45
267	Re: Pinto-Fraga et al.: Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial ( <i>Ophthalmology</i> 2016;123:141-153). <i>Ophthalmology</i> , 2017, 124, e14.	2.5	3
268	Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 117, 14-28.	2.0	131
269	Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. <i>Journal of Optometry</i> , 2017, 10, 258-264.	0.7	14
270	Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations. <i>Pharmaceutical Research</i> , 2017, 34, 2862-2872.	1.7	11
271	Achievements and Limits of Current Medical Therapy of Glaucoma. <i>Developments in Ophthalmology</i> , 2017, 59, 1-14.	0.1	27
272	Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 670-677.	0.6	14
273	TFOS DEWS II Management and Therapy Report. <i>Ocular Surface</i> , 2017, 15, 575-628.	2.2	839
274	TFOS DEWS II iatrogenic report. <i>Ocular Surface</i> , 2017, 15, 511-538.	2.2	304

#	ARTICLE	IF	CITATIONS
275	European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation. British Journal of Ophthalmology, 2017, 101, 130-195.	2.1	216
276	Pharmacotherapy of glaucoma: new opportunities, old challenges. Expert Opinion on Pharmacotherapy, 2017, 18, 1289-1290.	0.9	3
277	Glad Pressâ€™n Seal for the Treatment of Chronic Exposure Keratopathy. Ophthalmic Plastic and Reconstructive Surgery, 2017, 33, 152-153.	0.4	2
278	Re: â€™Diplopia and Symblepharon Following Muellerâ€™s Muscle Conjunctival Resection in Patients on Long-Term Multiple Antiglaucoma Medicationsâ€™. Ophthalmic Plastic and Reconstructive Surgery, 2017, 33, 151-152.	0.4	0
279	Reply re: â€™Diplopia and Symblepharon Following Mullerâ€™s Muscle Conjunctival Resection in Patients on Long-Term Multiple Antiglaucoma Medicationsâ€™. Ophthalmic Plastic and Reconstructive Surgery, 2017, 33, 152-152.	0.4	2
280	Efficacy of 2 Trabecular Micro-Bypass Stents During Phacoemulsification for Mild to Advanced Primary Open-angle Glaucoma Controlled With Topical Hypotensive Medications. Journal of Glaucoma, 2017, 26, 1149-1154.	0.8	13
281	Novel technologies for the delivery of ocular therapeutics in glaucoma. Journal of Drug Delivery Science and Technology, 2017, 42, 181-192.	1.4	17
282	Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: InÂˆvitro and exÂˆvivo functionality studies in corneal epithelial cells. Experimental Eye Research, 2017, 154, 79-87.	1.2	12
283	Tear fluid-eye drops compatibility assessment using surface tension. Drug Development and Industrial Pharmacy, 2017, 43, 275-282.	0.9	28
284	Nanotechnology-based strategies for treatment of ocular disease. Acta Pharmaceutica Sinica B, 2017, 7, 281-291.	5.7	257
285	The Risk of Microbial Contamination in Multiple-Dose Preservative-Free Ophthalmic Preparations. Biological and Pharmaceutical Bulletin, 2017, 40, 182-186.	0.6	4
286	A Sorption Study between Ophthalmic Drugs and Multi Dose Eyedroppers in Simulated Use Conditions. Pharmaceutical Technology in Hospital Pharmacy, 2017, 2, .	0.4	4
287	Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clinical Ophthalmology, 2017, Volume 11, 1583-1600.	0.9	133
288	Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Design, Development and Therapy, 2017, Volume 11, 1871-1879.	2.0	18
289	The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells. , 2017, 58, 2406.		79
290	A Comparison of the Effects of Benzalkonium Chloride on Ocular Surfaces between C57BL/6 and BALB/c Mice. International Journal of Molecular Sciences, 2017, 18, 509.	1.8	29
291	Analysis of the Pathogenic Factors and Management of Dry Eye in Ocular Surface Disorders. International Journal of Molecular Sciences, 2017, 18, 1764.	1.8	30
292	The Role of the P2X7 Receptor in Ocular Stresses: A Potential Therapeutic Target. Vision (Switzerland), 2017, 1, 14.	0.5	8



#	ARTICLE	IF	CITATIONS
293	Surface Chemistry Interactions of Cationorm with Films by Human Meibum and Tear Film Compounds. International Journal of Molecular Sciences, 2017, 18, 1558.	1.8	26
295	Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost. Journal of Ophthalmology, 2017, 2017, 1-6.	0.6	12
296	Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clinical Ophthalmology, 2017, Volume 11, 557-566.	0.9	23
297	Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. PLoS ONE, 2017, 12, e0181550.	1.1	28
298	Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0183142.	1.1	305
299	Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. Clinical Ophthalmology, 2017, Volume 11, 1051-1064.	0.9	13
300	In Vivo Confocal Imaging of the Conjunctiva as a Predictive Tool for the Glaucoma Filtration Surgery Outcome. , 2017, 58, BIO114.		34
301	The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study. Clinical Ophthalmology, 2017, Volume 11, 1175-1181.	0.9	3
302	A STUDY ON FORCED DEGRADATION AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION OF BENZALKONIUM CHLORIDE IN AZELASTINE HYDROCHORIDE PHARMACEUTICAL OPHTHALMIC FORMULATION. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10, 374.	0.3	3
303	Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells. Korean Journal of Physiology and Pharmacology, 2017, 21, 189.	0.6	2
304	Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye. Ocular Surface, 2018, 16, 289-293.	2.2	39
305	High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 387-394.	0.6	16
306	Meibomian Gland Features and Conjunctival Goblet Cell Density in Glaucomatous Patients Controlled With Prostaglandin/Timolol Fixed Combinations: A Case Control, Cross-sectional Study. Journal of Glaucoma, 2018, 27, 364-370.	0.8	26
307	Wound healing in the eye: Therapeutic prospects. Advanced Drug Delivery Reviews, 2018, 126, 162-176.	6.6	53
308	Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsification-XEN Gel Implant Surgery: 1-Year Results. Journal of Glaucoma, 2018, 27, 140-147.	0.8	133
309	A standardized extract of Rhynchosia volubilis Lour. exerts a protective effect on benzalkonium chloride-induced mouse dry eye model. Journal of Ethnopharmacology, 2018, 215, 91-100.	2.0	11
310	Effects of 20% Human Serum on Corneal Epithelial Toxicity Induced by Benzalkonium Chloride: In Vitro and Clinical Studies. Cornea, 2018, 37, 617-623.	0.9	14
311	Neurotrophic keratopathy. Progress in Retinal and Eye Research, 2018, 66, 107-131.	7.3	250

#	ARTICLE	IF	CITATIONS
312	Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 888-894.	1.3	15
314	Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. <i>European Journal of Ophthalmology</i> , 2018, 28, 385-392.	0.7	17
315	The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board. <i>International Ophthalmology</i> , 2018, 38, 875-895.	0.6	21
316	N-hydroxymethylglycinate with EDTA is an efficient eye drop preservative with very low toxicity: an in vitro comparative study. <i>Cutaneous and Ocular Toxicology</i> , 2018, 37, 71-76.	0.5	6
317	Correlations of In Vitro Assays for Assessing Cytotoxicity and Biocompatibility of Contact Lens Multipurpose Solutions. <i>Eye and Contact Lens</i> , 2018, 44, S97-S105.	0.8	5
318	Trimethylamine N-oxide (TMAO) is a counteracting solute of benzyl alcohol for multi-dose formulation of immunoglobulin. <i>International Journal of Biological Macromolecules</i> , 2018, 107, 984-989.	3.6	5
319	Microbial Stability of Pharmaceutical and Cosmetic Products. <i>AAPS PharmSciTech</i> , 2018, 19, 60-78.	1.5	57
320	DNA nanoparticles for ophthalmic drug delivery. <i>Biomaterials</i> , 2018, 157, 98-106.	5.7	69
321	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. <i>Drugs</i> , 2018, 78, 39-64.	4.9	43
322	Risk assessment of benzalkonium chloride in cosmetic products. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2018, 21, 8-23.	2.9	49
323	Aqueous-Deficient Dry Eye Disease: Evaluation and Management. , 2018, , 1-16.		0
324	Management of Glaucoma in Patients with Ocular Surface Disease. , 2018, , 125-138.		0
325	Nanomicelle-Assisted Targeted Ocular Delivery with Enhanced Antiinflammatory Efficacy In Vivo. <i>Advanced Science</i> , 2018, 5, 1700455.	5.6	49
326	Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases. <i>Journal of Glaucoma</i> , 2018, 27, 1105-1111.	0.8	25
327	Anterior-Segment Optical Coherence Tomography and Scanning Electron Microscopy to Evaluate Corneal Epithelial Changes in Patients Undergoing Glaucoma Therapy. <i>Cornea</i> , 2018, 37, 1522-1526.	0.9	15
328	DEVELOPMENT AND CHARACTERIZATION OF INDOMETHACIN-LOADED MUCOADHESIVE NANOSTRUCTURED LIPID CARRIERS FOR TOPICAL OCULAR DELIVERY. <i>International Journal of Applied Pharmaceutics</i> , 2018, 10, 91.	0.3	11
329	Shelf Life and Efficacy of Diagnostic Eye Drops. <i>Optometry and Vision Science</i> , 2018, 95, 947-952.	0.6	4
330	Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. <i>Journal Francais D'Ophthalmologie</i> , 2018, 41, 945-954.	0.2	16

#	ARTICLE	IF	CITATIONS
331	Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 2399-2407.	0.9	25
332	Stability of a 50µg/mL Ceftazidime Eye-Drops Formulation. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2018, 3, 219-226.	0.4	3
333	Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1981-1988.	0.9	17
335	Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1519-1525.	0.9	12
336	Ocular allergy as a risk factor for dry eye in adults and children. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 398-403.	1.1	35
337	Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 1028-1034.	1.3	12
338	Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1027-1039.	0.9	29
339	Glaucoma therapy: preservative-free for all?. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 707-717.	0.9	42
340	0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice. , 2018, 59, 3375.		29
341	Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma. <i>International Medical Case Reports Journal</i> , 2018, Volume 11, 97-103.	0.3	18
342	Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. <i>Frontiers in Medicine</i> , 2018, 5, 33.	1.2	52
343	Preservatives in glaucoma medication. <i>British Journal of Ophthalmology</i> , 2018, 102, 1497-1503.	2.1	83
344	A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits. <i>BMC Veterinary Research</i> , 2018, 14, 39.	0.7	2
345	Novel approaches for improving stability of cysteamine formulations. <i>International Journal of Pharmaceutics</i> , 2018, 549, 466-475.	2.6	7
346	Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. <i>Advances in Therapy</i> , 2018, 35, 796-808.	1.3	9
347	Ocular Surface Disease in the Glaucoma Patient. <i>International Ophthalmology Clinics</i> , 2018, 58, 23-33.	0.3	6
348	Toxic medications in Leber's hereditary optic neuropathy. <i>Mitochondrion</i> , 2019, 46, 270-277.	1.6	21
349	The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. <i>European Journal of Ophthalmology</i> , 2019, 29, 210-215.	0.7	31

#	ARTICLE	IF	CITATIONS
350	Real-world Case Series of iStent or iStent inject Trabecular Micro-Bypass Stents Combined with Cataract Surgery. <i>Ophthalmology and Therapy</i> , 2019, 8, 549-561.	1.0	41
351	Cross-Linked Hyaluronic Acid as Tear Film Substitute. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 381-387.	0.6	25
352	Effect of Topical Prostaglandin F <sub>2</sub> ± Analogs on Selected Oxidative Stress Parameters in the Tear Film. <i>Medicina (Lithuania)</i> , 2019, 55, 366.	0.8	8
353	Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers. <i>Polymers</i> , 2019, 11, 1213.	2.0	6
354	Optical Coherence Tomography Angiography Evaluation of Conjunctival Vessels During Filtering Surgery. <i>Translational Vision Science and Technology</i> , 2019, 8, 4.	1.1	13
355	&lt;p&gt;Photothermal conversion hydrogel based mini-eye patch for relieving dry eye with long-term use of the light-emitting screen&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 5125-5133.	3.3	22
356	Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. <i>PLoS ONE</i> , 2019, 14, e0218886.	1.1	12
357	In Vitro Cytotoxicity Screening as a Criterion for the Rational Selection of Tear Substitutes. , 2019, , .		0
358	Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues. <i>Chonnam Medical Journal</i> , 2019, 55, 156.	0.5	13
359	Gelam honey promotes ex vivo corneal fibroblasts wound healing. <i>Cytotecology</i> , 2019, 71, 1121-1135.	0.7	4
360	Application of Microfluidics in Wearable Devices. <i>Small Methods</i> , 2019, 3, 1900688.	4.6	37
361	Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents. <i>BMC Ophthalmology</i> , 2019, 19, 217.	0.6	2
363	Allergic contact dermatitis caused by topical ophthalmic medications: Keep an eye on it!. <i>Contact Dermatitis</i> , 2019, 80, 291-297.	0.8	39
364	&lt;p&gt;The use of preservatives in dry eye drops&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1409-1425.	0.9	58
365	One-Year Comparative Evaluation of iStent or iStent inject Implantation Combined with Cataract Surgery in a Single Center. <i>Advances in Therapy</i> , 2019, 36, 2797-2810.	1.3	37
366	Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits. <i>Journal of Clinical Medicine</i> , 2019, 8, 1227.	1.0	30
367	Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome. <i>Acta Biomaterialia</i> , 2019, 99, 350-362.	4.1	40
368	&lt;p&gt;Ab interno canaloplasty combined with trabecular bypass stenting in eyes with primary open-angle glaucoma&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1533-1542.	0.9	10

#	ARTICLE	IF	CITATIONS
369	360&deg; ab-interno trabeculotomy in refractory primary open-angle glaucoma. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 161-168.	0.9	30
370	Punctal and canalicular plugs: Indications, efficacy and safety. <i>Journal Francais D'Ophtalmologie</i> , 2019, 42, e95-e104.	0.2	11
371	Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. <i>Journal of Medical Economics</i> , 2019, 22, 390-401.	1.0	33
372	Second-Generation Trabecular Micro-Bypass Stents as Standalone Treatment for Glaucoma: A 36-Month Prospective Study. <i>Advances in Therapy</i> , 2019, 36, 1606-1617.	1.3	45
373	Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 83-91.	2.0	16
374	Topical sustained drug delivery to the retina with a drug-eluting contact lens. <i>Biomaterials</i> , 2019, 217, 119285.	5.7	74
375	Effect of a Cationic Surfactant on Microemulsion Globules and Drug Release from Hydrogel Contact Lenses. <i>Pharmaceutics</i> , 2019, 11, 262.	2.0	24
376	Vitreomacular Interface Abnormalities and Glaucoma in an Elderly Population (The MONTRACHET) Tj ETQq1 1 0.784314 rgBT <sub>6</sub> /Overload		
377	Optimization of intraocular lens hydrogels for dual drug release: Experimentation and modelling. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 51-57.	2.0	12
378	Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol. <i>Scientific Reports</i> , 2019, 9, 7491.	1.6	11
379	Medical Treatment Strategy for Glaucoma. , 2019, , 87-113.		1
380	Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 106, 81-89.	1.3	13
381	Twenty-four-hour efficacy of the brinzolamide 1%/brimonidine 0.2% fixed combination: what does the new evidence tell us?. <i>Annals of Eye Science</i> , 0, 4, 11-11.	1.1	0
382	IMI " Clinical Management Guidelines Report. , 2019, 60, M184.		107
383	Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. <i>Ocular Surface</i> , 2019, 17, 412-423.	2.2	56
384	Effects of Anti-Glaucoma Prostaglandin Ophthalmic Solutions on Cultured Human Corneal Epithelial Cells. <i>Current Eye Research</i> , 2019, 44, 856-862.	0.7	9
385	An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. <i>Scientific Reports</i> , 2019, 9, 4282.	1.6	9
386	The Role of Surface Active Agents in Ophthalmic Drug Delivery: A Comprehensive Review. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1923-1933.	1.6	32

#	ARTICLE	IF	CITATIONS
388	Cultivated Limbal Stem Cell Transplantation: Indications and Technique. <i>Essentials in Ophthalmology</i> , 2019, , 277-290.	0.0	0
389	Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye. <i>Frontiers in Public Health</i> , 2019, 7, 363.	1.3	5
390	Potential toxicity of topical ocular solutions. <i>Cmaj</i> , 2019, 191, E898-E898.	0.9	1
391	Modern Preservatives of Microbiological Stability (Review). <i>Pharmaceutical Chemistry Journal</i> , 2019, 53, 564-571.	0.3	16
392	Ocular Fluid Dynamics. <i>Modeling and Simulation in Science, Engineering and Technology</i> , 2019, , .	0.4	9
393	Commercial Quinolone Ear Drops Cause Perforations in Intact Rat Tympanic Membranes. <i>Otology and Neurotology</i> , 2019, 40, 1386-1391.	0.7	9
394	Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension. <i>Journal of Glaucoma</i> , 2019, 28, 498-506.	0.8	16
395	Impact of Nanostructured Lipid Carriers as an Artificial Tear Film in a Rabbit Evaporative Dry Eye Model. <i>Cornea</i> , 2019, 38, 485-491.	0.9	20
396	Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment. <i>Journal of Glaucoma</i> , 2019, 28, 325-333.	0.8	11
397	Role of corneal nerves in ocular surface homeostasis and disease. <i>Acta Ophthalmologica</i> , 2019, 97, 137-145.	0.6	125
398	In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells. <i>Annals of Anatomy</i> , 2019, 222, 129-138.	1.0	17
400	Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. <i>Eye and Contact Lens</i> , 2019, 45, 11-18.	0.8	92
401	New Classes of Polycationic Compounds as Preservatives for Ophthalmic Formulations. <i>Pharmaceutical Research</i> , 2019, 36, 11.	1.7	2
402	Safety of sodium hyaluronate eye drop with C12-benzalkonium chloride. <i>Cutaneous and Ocular Toxicology</i> , 2019, 38, 156-160.	0.5	4
403	Brimonidine tartrate for the treatment of glaucoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 115-122.	0.9	52
404	Reconsidering the central role of mucins in dry eye and ocular surface diseases. <i>Progress in Retinal and Eye Research</i> , 2019, 71, 68-87.	7.3	78
405	Effects of corneal injury on ciliary nerve fibre activity and corneal nociception in mice: A behavioural and electrophysiological study. <i>European Journal of Pain</i> , 2019, 23, 589-602.	1.4	22
406	Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. <i>European Journal of Ophthalmology</i> , 2019, 29, 645-653.	0.7	18

#	ARTICLE	IF	CITATIONS
407	Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. <i>American Journal of Ophthalmology</i> , 2019, 198, 181-192.	1.7	16
408	The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review. <i>Journal of Current Ophthalmology</i> , 2019, 31, 8-15.	0.3	26
409	Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients. <i>International Ophthalmology</i> , 2019, 39, 105-109.	0.6	16
410	Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 484-496.	1.0	10
411	Preservative-free <i>&lt;i&gt;</i> versus <i>&lt;/i&gt;</i> preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 21-24.	0.5	13
412	Presbyopia and the aging eye: Existing refractive approaches and their potential impact on dry eye signs and symptoms. <i>Contact Lens and Anterior Eye</i> , 2020, 43, 103-114.	0.8	20
413	Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro. <i>Toxicology Letters</i> , 2020, 319, 74-84.	0.4	27
414	Evaluation of corneal epithelial thickness in glaucomatous patients using anteriorâ€segment optical coherence tomography. <i>Journal of Biophotonics</i> , 2020, 13, e201900095.	1.1	7
415	Membrane-associated mucins of the ocular surface: New genes, new protein functions and new biological roles in human and mouse. <i>Progress in Retinal and Eye Research</i> , 2020, 75, 100777.	7.3	30
416	The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice Treated with Antiglaucoma Eye Medications. <i>Diagnostics</i> , 2020, 10, 20.	1.3	7
417	Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118734.	2.6	38
418	Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. <i>Ocular Surface</i> , 2020, 18, 158-169.	2.2	56
419	Cytotoxicity of Ear Drop Excipients in Human and Mouse Tympanic Membrane Fibroblasts. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 204-210.	1.1	3
420	Burden of dry eye disease in Germany: a retrospective observational study using German claims data. <i>Acta Ophthalmologica</i> , 2020, 98, e504-e512.	0.6	14
421	A Novel Integrated Active Herbal Formulation Ameliorates Dry Eye Syndrome by Inhibiting Inflammation and Oxidative Stress and Enhancing Glycosylated Phosphoproteins in Rats. <i>Pharmaceutics</i> , 2020, 13, 295.	1.7	10
422	Inflammation in Glaucoma: From the back to the front of the eye, and beyond. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100916.	7.3	183
423	Lipidomic analysis of human corneal epithelial cells exposed to ocular irritants highlights the role of phospholipid and sphingolipid metabolisms in detergent toxicity mechanisms. <i>Biochimie</i> , 2020, 178, 148-157.	1.3	14
424	Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs. <i>International Ophthalmology</i> , 2020, 40, 2585-2592.	0.6	3

#	ARTICLE	IF	CITATIONS
425	<p>&lt;p>&gt;Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients&lt;/p>&lt;/p>. Clinical Ophthalmology, 2020, Volume 14, 3109-3119.	0.9	14
426	&lt;p>&lt;p>&gt;Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments&lt;/p>&lt;/p>. Clinical Ophthalmology, 2020, Volume 14, 3675-3680.	0.9	17
427	Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opinion on Drug Delivery, 2020, 18, 1-18.	2.4	14
428	Why Chain Length of Hyaluronan in Eye Drops Matters. Diagnostics, 2020, 10, 511.	1.3	17
429	Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Advances, 2020, 10, 27835-27855.	1.7	142
430	Current and new pharmacotherapeutic approaches for glaucoma. Expert Opinion on Pharmacotherapy, 2020, 21, 2027-2040.	0.9	21
431	Acupuncture for the treatment of dry eye. Medicine (United States), 2020, 99, e21625.	0.4	2
432	Protecting the Ocular Surface at the Time of Cataract Surgery: Intracameral Mydriatic and Anaesthetic Combination Versus A Standard Topical Protocol. Ophthalmology and Therapy, 2020, 9, 1055-1067.	1.0	9
433	Aerobic Exercise Increases Tear Secretion and Decreases Inflammatory Cytokines in Healthy Subjects. Asia-Pacific Journal of Ophthalmology, 2020, 9, 404-411.	1.3	4
434	Ab interno trabeculotomy combined with cataract extraction in eyes with primary open-angle glaucoma. Journal of International Medical Research, 2020, 48, 030006052095744.	0.4	2
436	Seasonal variation of intra-ocular pressure in glaucoma with and without dry eye. Scientific Reports, 2020, 10, 13949.	1.6	7
437	Contact Lenses as Drug Delivery System for Glaucoma: A Review. Applied Sciences (Switzerland), 2020, 10, 5151.	1.3	22
438	Developing a framework regarding a complex risk based methodology in the evaluation of hazards associated with medicinal products sourced via the internet. Saudi Pharmaceutical Journal, 2020, 28, 1733-1742.	1.2	14
439	SARS-CoV-2 human disinfection chambers: a critical analysis. Occupational Medicine, 2020, 70, 330-334.	0.8	12
440	<p><p>&lt;p>&lt;p>&gt;The Pro-Fibrotic Behavior of Human Tenon&#x2019;s Capsule Fibroblasts in Medically Treated Glaucoma Patients</p>&lt;/p>&lt;/p>&lt;/p>. Clinical Ophthalmology, 2020, Volume 14, 1391-1402.	0.9	11
441	Response to: Management of Glaucoma in Pregnancy. Journal of Glaucoma, 2020, 29, e27-e27.	0.8	0
442	Profiling ocular surface responses to preserved and non&#x2013;preserved topical glaucoma medications: A 2&#x2013;year randomized evaluation study. Clinical and Experimental Ophthalmology, 2020, 48, 973-982.	1.3	27
443	Argon Laser Iridoplasty for Plateau Iris Syndrome: Long-Term Outcomes of 48 Eyes. Journal of Glaucoma, 2020, 29, e27-e27.	0.8	0



#	ARTICLE	IF	CITATIONS
444	<p></p>Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Reversal of Edematous Punctal Occlusion</p>. Clinical Ophthalmology, 2020, Volume 14, 1467-1472.	0.9	8
445	Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Advanced Drug Delivery Reviews, 2020, 158, 73-90.	6.6	83
446	In vivo confocal microscopy: qualitative investigation of the conjunctival and corneal surface in open angle glaucomatous patients undergoing the XEN-Gel implant, trabeculectomy or medical therapy. Eye and Vision (London, England), 2020, 7, 15.	1.4	20
447	Association of the Somatostatin Analog Octreotide With Magnetic Nanoparticles for Intraocular Delivery: A Possible Approach for the Treatment of Diabetic Retinopathy. Frontiers in Bioengineering and Biotechnology, 2020, 8, 144.	2.0	26
448	Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film. Cutaneous and Ocular Toxicology, 2020, 39, 260-268.	0.5	11
449	Effects of Benzalkonium Chloride and Preservative-Free Composition on the Corneal Epithelium Cells. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 672-678.	0.6	6
450	Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries. Ophthalmology and Therapy, 2020, 9, 597-608.	1.0	2
451	Management of Glaucoma in Pregnancy. Journal of Glaucoma, 2020, 29, e26-e27.	0.8	0
452	Cytoprotective effect of amniotic membrane extracts on human corneal epithelial cells exposed to benzalkonium chloride in vitro. Annals of Eye Science, 0, 5, 11-11.	1.1	1
453	Second-Generation Trabecular Micro-Bypass (iStent inject) with Cataract Surgery in Eyes with Normal-Tension Glaucoma: One-Year Outcomes of a Multi-Centre Study. Ophthalmology and Therapy, 2020, 9, 585-596.	1.0	23
454	<p></p>Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy</p>. Clinical Ophthalmology, 2020, Volume 14, 89-94.	0.9	12
455	Effects of a prostaglandin F2alpha derivative glaucoma drug on EGF expression and E-cadherin expression in a corneal epithelial cell line. Cutaneous and Ocular Toxicology, 2020, 39, 75-82.	0.5	2
456	Therapeutic Contact Lens for Scavenging Excessive Reactive Oxygen Species on the Ocular Surface. ACS Nano, 2020, 14, 2483-2496.	7.3	68
457	A contemporary look at allergic conjunctivitis. Allergy, Asthma and Clinical Immunology, 2020, 16, 5.	0.9	54
458	<p></p>Four-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication</p>. Clinical Ophthalmology, 2020, Volume 14, 71-80.	0.9	23
459	Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmologica, 2020, 98, e876-e881.	0.6	16
460	The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations. BMC Pharmacology & Toxicology, 2020, 21, 24.	1.0	3
461	Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Cutaneous and Ocular Toxicology, 2020, 39, 158-164.	0.5	7

#	ARTICLE	IF	CITATIONS
462	A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 522-528.	0.6	9
463	Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents. <i>Pharmaceutics</i> , 2020, 12, 306.	2.0	23
464	A technique for shotgun proteomic analysis of the precorneal tear film in dogs with naturally occurring primary glaucoma. <i>Veterinary Ophthalmology</i> , 2021, 24, 131-145.	0.6	3
465	Personalising surgical treatments for glaucoma patients. <i>Progress in Retinal and Eye Research</i> , 2021, 81, 100879.	7.3	22
466	Drugs Used in Ophthalmology. , 2021, , 413-499.		0
467	Gonioscopy-Assisted Transluminal Trabeculotomy in Younger to Middle-Aged Adults: One-Year Outcomes. <i>Ophthalmology Glaucoma</i> , 2021, 4, 162-172.	0.9	24
468	Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye. <i>Australasian journal of optometry, The</i> , 2021, 104, 315-322.	0.6	14
469	Assessment of response to multimodal management of neurotrophic corneal disease. <i>Ocular Surface</i> , 2021, 19, 330-335.	2.2	13
470	Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future. <i>Advances in Therapy</i> , 2021, 38, 24-51.	1.3	16
471	Dropless cataract surgery: modernizing perioperative medical therapy to improve outcomes and patient satisfaction. <i>Current Opinion in Ophthalmology</i> , 2021, 32, S1-S12.	1.3	20
472	Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives. <i>British Journal of Ophthalmology</i> , 2021, 105, 141-148.	2.1	11
473	The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 453-466.	1.0	16
474	Effects of Intravitreal Injection on Ocular Surface and Anterior Segment Parameters. <i>Beyoglu Eye Journal</i> , 2021, 6, 84-89.	0.1	1
476	Overview of Polyphenols and Polyphenol-rich Extracts as Modulators of Inflammatory Response in Dry Eye Syndrome. <i>Food Reviews International</i> , 2022, 38, 501-528.	4.3	4
477	Preventing glaucoma progression using the trabecular micro-bypass implant iStent inject®. A cost-effectiveness analysis. <i>Revista Brasileira De Oftalmologia</i> , 2021, 80, .	0.1	0
478	Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial. <i>Journal of Glaucoma</i> , 2021, 30, 545-551.	0.8	15
479	An Evidence-Based Strategic Approach to Prevention and Treatment of Dry Eye Disease, a Modern Global Epidemic. <i>Healthcare (Switzerland)</i> , 2021, 9, 89.	1.0	17
480	Role of CD4 <sup>+</sup> T Helper Cells in the Development of BAC-Induced Dry Eye Syndrome in Mice. , 2021, 62, 25.		14

#	ARTICLE	IF	CITATIONS
481	Formulation Considerations for the Management of Dry Eye Disease. <i>Pharmaceutics</i> , 2021, 13, 207.	2.0	56
482	Do topical ocular antihypertensives affect Dacryocystorhinostomy outcomes: The Coventry experience. <i>Eye</i> , 2022, 36, 135-139.	1.1	2
483	Biopolymer-based nanoparticles with tunable mucoadhesivity efficiently deliver therapeutics across the corneal barrier. <i>Materials Science and Engineering C</i> , 2021, 121, 111890.	3.8	10
484	The role of Gelam honey in accelerating reepithelialization of ex vivo corneal abrasion model. <i>Journal of Food Biochemistry</i> , 2021, 45, e13645.	1.2	4
485	Iatrogenic corneal diseases or conditions. <i>Experimental Eye Research</i> , 2021, 203, 108376.	1.2	4
486	Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders. <i>Nanomedicine</i> , 2021, 16, 401-414.	1.7	6
487	Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 931-938.	0.9	6
488	Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma. <i>Seminars in Ophthalmology</i> , 2021, 36, 103-109.	0.8	2
490	Safety and Tolerability of an Eye Drop Based on 0.6% Povidone-Iodine Nanoemulsion in Dry Eye Patients. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 90-96.	0.6	19
491	Effect of red ginseng on visual function and vision-related quality of life in patients with glaucoma. <i>Journal of Ginseng Research</i> , 2021, 45, 676-682.	3.0	3
492	Electroanalysis of Benzalkonium Chloride in Ophthalmic Formulation by Boron-Doped Diamond Electrode. <i>Electroanalysis</i> , 2021, 33, 1137-1142.	1.5	5
493	Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110065.	0.7	1
494	A therapeutic strategy for Sjögren's syndrome dry eye. , 2021, , 109-122.		0
495	The Results of Transscleral Diode Laser Cyclophotocoagulation in Micropulse Mode Treatment in Patients with Primary Subcompensated Open-Angle Glaucoma and Toxic-Allergic Syndrome of the Ocular Surface. <i>Oftalmologiya</i> , 2021, 18, 77-82.	0.2	0
496	Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. <i>Advances in Therapy</i> , 2021, 38, 3019-3031.	1.3	13
497	Age-related changes in ocular mucosal tolerance: Lessons learned from gut and respiratory tract immunity. <i>Immunology</i> , 2021, 164, 43-56.	2.0	14
498	Punctal Congestion Syndrome: A Reversible, Functional Punctal Stenosis Causing Epiphora in the Setting of Chronic Pretarsal Conjunctivitis. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, S92-S97.	0.4	5
499	Oxidative and antioxidative stress markers in dry eye disease: A systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2022, 100, 45-57.	0.6	20

#	ARTICLE	IF	CITATIONS
500	Comparison of Topical Instillation From Single-dose and Multidose Eye Drop Containers in Glaucoma: A Multicenter Randomized Cross-sectional Trial. <i>Journal of Glaucoma</i> , 2021, 30, 718-724.	0.8	3
501	Relationship between ocular surface disease and patient's satisfaction among cataract surgical patients in Nigeria. <i>International Ophthalmology</i> , 2021, 41, 3163-3170.	0.6	4
502	The two-faced effects of nerves and neuropeptides in corneal diseases. <i>Progress in Retinal and Eye Research</i> , 2022, 86, 100974.	7.3	28
503	Confocal Microscopy and Anterior Segment Optical Coherence Tomography Imaging of the Ocular Surface and Bleb Morphology in Medically and Surgically Treated Glaucoma Patients: A Review. <i>Pharmaceuticals</i> , 2021, 14, 581.	1.7	7
504	Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review. <i>Acta Ophthalmologica</i> , 2021, , .	0.6	3
505	Glaukom-“Erkrankung der Augenoberfläche (”ocular surface disease”)“ Augentropfen-“Konservierungsmittel: Ein Überblick. <i>Spektrum Der Augenheilkunde</i> , 2021, 35, 201-208.	0.2	0
506	12-month clinical outcomes of combined phacoemulsification and ab interno trabeculectomy for open-angle glaucoma in the United Kingdom. <i>PLoS ONE</i> , 2021, 16, e0252826.	1.1	4
507	Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma. <i>Korean Journal of Ophthalmology: KJO</i> , 2021, 35, 235-241.	0.5	5
508	Omidenepag isopropyl ophthalmic solution for open-angle glaucoma and ocular hypertension: an update. <i>Expert Review of Ophthalmology</i> , 2021, 16, 243-250.	0.3	5
509	Optimization of goblet cell density quantification methods. <i>Experimental Eye Research</i> , 2021, 207, 108607.	1.2	0
510	Deepening of lipidome annotation by associating cross-metathesis reaction with mass spectrometry: application to an in vitro model of corneal toxicity. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4825-4836.	1.9	3
511	Relieving the symptoms of dry eye disease: update on lubricating eye drops containing hydroxypropyl-guar. <i>Australasian journal of optometry, The</i> , 2021, 104, 1-9.	0.6	4
512	Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial. <i>Scientific Reports</i> , 2021, 11, 14971.	1.6	6
513	Binding affinity of benzalkonium chloride on contact lens surfaces and the effects on their physical properties. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 203, 111744.	2.5	7
514	Standalone Trabeculotomy and Viscodilation of Schlemm's Canal and Collector Channels in Open-Angle Glaucoma Using the OMNI Surgical System: 24-Month Outcomes. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 3121-3129.	0.9	21
515	Ocular benzalkonium chloride exposure: problems and solutions. <i>Eye</i> , 2022, 36, 361-368.	1.1	74
516	PreserFlo MicroShunt® exposure: a case series. <i>BMC Ophthalmology</i> , 2021, 21, 273.	0.6	9
517	Dry Eye and Phacoemulsification Cataract Surgery: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 649030.	1.2	17

#	ARTICLE	IF	CITATIONS
518	Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. <i>International Ophthalmology</i> , 2021, 41, 3825-3835.	0.6	10
519	<em>In vivo</em> model of Hirschsprung-associated enterocolitis using benzalkonium chloride. <i>Medical Journal of Indonesia</i> , 0, , .	0.2	1
520	Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 247-253.	1.0	3
521	Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1945-1955.	1.0	2
522	Effects of quinolone and poloxamer otic suspension on rat tympanic membranes. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2021, 147, 110805.	0.4	0
523	Glaucoma and Dry Eye. , 0, , .		0
524	Benzalkonium chloride-induced myofibroblastic transdifferentiation of Tenonâ€™s capsule fibroblasts is inhibited by coculture with corneal epithelial cells or by interleukin-10. <i>Scientific Reports</i> , 2021, 11, 16096.	1.6	0
525	Effects of Eye Drops Containing Hyaluronic Acid-Nimesulide Conjugates in a Benzalkonium Chloride-Induced Experimental Dry Eye Rabbit Model. <i>Pharmaceutics</i> , 2021, 13, 1366.	2.0	9
526	The History of Surfactants and Review of Their Allergic and Irritant Properties. <i>Dermatitis</i> , 2021, 32, 289-297.	0.8	13
527	Targeted mesoporous silica nanoparticles for improved inhibition of disinfectant resistant <i>Listeria monocytogenes</i> and lower environmental pollution. <i>Journal of Hazardous Materials</i> , 2021, 418, 126364.	6.5	10
529	In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models. <i>Translational Vision Science and Technology</i> , 2021, 10, 14.	1.1	4
530	When is preservative-free therapy of glaucoma needed and advisable?. <i>Rossiiskii Oftal'mologicheskii Zhurnal</i> , 2021, 14, 25-31.	0.1	0
531	Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film. <i>BMC Ophthalmology</i> , 2021, 21, 319.	0.6	8
532	Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development. <i>Frontiers in Medicine</i> , 2021, 8, 733080.	1.2	33
533	Bitot-like spots in children with normal vitamin A levels. <i>Eye</i> , 2022, 36, 1896-1899.	1.1	1
534	Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial. <i>International Journal of Ophthalmology</i> , 2021, 14, 1539-1547.	0.5	4
535	Injectable bio-responsive hydrogel for therapy of inflammation related eyelid diseases. <i>Bioactive Materials</i> , 2021, 6, 3062-3073.	8.6	22
536	A comparison between the effect of topical tafluprost and latanoprost on intraocular pressure in healthy male guinea pigs. <i>Journal of Exotic Pet Medicine</i> , 2021, 39, 91-95.	0.2	3

#	ARTICLE	IF	CITATIONS
537	Essential oils and chitosan as alternatives to chemical preservatives for fish and fisheries products: A review. <i>Food Control</i> , 2021, 129, 108244.	2.8	65
538	Benzalkonium Chloride Disinfectants Induce Apoptosis, Inhibit Proliferation, and Activate the Integrated Stress Response in a 3-D <i>in Vitro</i> Model of Neurodevelopment. <i>Chemical Research in Toxicology</i> , 2021, 34, 1265-1274.	1.7	6
540	Lipidomic analysis of epithelial corneal cells following hyperosmolarity and benzalkonium chloride exposure: New insights in dry eye disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158728.	1.2	14
541	Toxicity of Intracameral Injection of Fourth-Generation Fluoroquinolones on the Corneal Endothelium. <i>Cornea</i> , 2016, 35, 1631-1637.	0.9	11
542	Assessment of Corneal Epithelium Thickness in Glaucomatous Patients Undergoing Medical Treatment. <i>Journal of Glaucoma</i> , 2021, 30, 44-49.	0.8	5
543	Three-Year Outcomes of Second-generation Trabecular Micro-bypass Stents (iStent inject) With Phacoemulsification in Various Glaucoma Subtypes and Severities. <i>Journal of Glaucoma</i> , 2021, 30, 266-275.	0.8	22
544	Proliferative Capacity of <i>in Vitro</i> Corneal Epithelium: Role of Acacia Honey in the Initial Step of Wound Healing. <i>Journal of Medical and Bioengineering</i> , 2014, 3, 107-112.	0.5	2
545	Corneal Alterations Induced by Topical Application of Benzalkonium Chloride in Rabbit. <i>PLoS ONE</i> , 2011, 6, e26103.	1.1	74
546	Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study. <i>PLoS ONE</i> , 2012, 7, e33913.	1.1	31
547	Localization and Expression of Zonula Occludins-1 in the Rabbit Corneal Epithelium following Exposure to Benzalkonium Chloride. <i>PLoS ONE</i> , 2012, 7, e40893.	1.1	26
548	Effects of Benzalkonium Chloride on THP-1 Differentiated Macrophages <i>In Vitro</i> . <i>PLoS ONE</i> , 2013, 8, e72459.	1.1	27
549	Hybrid Formulations of Liposomes and Bioadhesive Polymers Improve the Hypotensive Effect of the Melatonin Analogue 5-MCA-NAT in Rabbit Eyes. <i>PLoS ONE</i> , 2014, 9, e110344.	1.1	29
550	Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study. <i>PLoS ONE</i> , 2015, 10, e0129419.	1.1	5
551	Suppression of TGF- $\beta$ 2 pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts <i>in vitro</i> . <i>PLoS ONE</i> , 2017, 12, e0172592.	1.1	72
552	Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects. <i>PLoS ONE</i> , 2017, 12, e0188534.	1.1	13
553	Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. <i>PLoS ONE</i> , 2018, 13, e0191398.	1.1	16
556	Conjunctivitis: A Systematic Review. <i>Journal of Ophthalmic and Vision Research</i> , 2020, 15, 372-395.	0.7	30
557	<p>&lt;p>Impact of Ocular Surface Disease Treatment in Patients with Glaucoma</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 103-111.	0.9	37

#	ARTICLE	IF	CITATIONS
558	<p><i>Stent Trabecular Micro-Bypass Stent Implantation with Cataract Surgery in a Japanese Glaucoma Population</i>. Clinical Ophthalmology, 2020, Volume 14, 3381-3391.	0.9	16
559	Structural and Molecular Tear Film Changes in Glaucoma. Current Medicinal Chemistry, 2019, 26, 4225-4240.	1.2	22
560	Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment. Current Medicinal Chemistry, 2019, 26, 4253-4261.	1.2	8
561	Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy. Current Neuropharmacology, 2018, 16, 993-1003.	1.4	18
562	Optimization of the Interaction between Diclofenac and Ibuprofen with Benzalkonium Chloride to Prepare Ocular Nanosuspension. Recent Patents on Drug Delivery and Formulation, 2020, 13, 301-309.	2.1	3
563	Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study. Open Ophthalmology Journal, 2016, 10, 146-153.	0.1	11
564	In Vivo Scanning Laser Confocal Microscopy of Conjunctival Goblet Cells in Medically-controlled Glaucoma. In Vivo, 2018, 32, 437-443.	0.6	11
565	Effects of Several Cosmetic Preservatives on ROS-Dependent Apoptosis of Rat Neural Progenitor Cells. Biomolecules and Therapeutics, 2018, 26, 608-615.	1.1	14
566	Allergic reactions to atropine eye drops for retardation of progressive myopia in children. Indian Journal of Ophthalmology, 2018, 66, 1446.	0.5	9
567	Autologous serum and sodium hyaluronate role in alkali corneal burn healing. Journal of the Arab Society for Medical Research, 2018, 13, 39.	0.0	2
568	Glaucoma medications in pregnancy. Oman Journal of Ophthalmology, 2018, 11, 195.	0.2	10
569	Dry Eye Disease after Cataract Surgery: Study of its Determinants and Risk Factors. Trk Oftalmoloji Dergisi, 2020, 50, 133-142.	0.4	20
570	Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial. Re:GEN Open, 2021, 1, 110-116.	0.7	2
571	The Efficacy and Safety of Preservative-containing and Preservative-free Brimonidine-Timolol Fixed Combination in Normal Tension Glaucoma. Journal of Korean Ophthalmological Society, 2021, 62, 1407-1414.	0.0	0
572	A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety, 2022, 21, 525-539.	1.0	7
573	Therapeutic nanocoating of ocular surface. Nano Today, 2021, 41, 101309.	6.2	13
574	Ocular Surface and Glaucoma. , 2012, , 138-154.		0
575	Comparison of Efficacy and Safety Evaluation of Latanoprost Formulations with and without Benzalkonium Chloride. Pharmacology & Pharmacy, 2013, 04, 377-384.	0.2	3

#	ARTICLE	IF	CITATIONS
577	Drug-induced ocular side effects. , 2015, , 47-343.		0
578	Ocular Preservatives: Risks and Recent Trends in Its Application in Ocular Drug Delivery (ODD). , 2016, , 253-276.		0
579	Medicamentosa keratoconjunctivitis: A case report. African Vision and Eye Health, 2016, 75, .	0.1	0
580	TafloTan, the first preservative-free prostaglandin F <sub>2</sub> analogue: treatment advantages in primary open-angle glaucoma patients. Ophthalmology Journal, 2016, 9, 59-68.	0.1	1
581	RELEVANCE OF OCULAR SURFACE DISEASE INDEX (OSDI) QUESTIONNAIRE IN MINIMISING OPTIC NERVE DAMAGE AMONG GLAUCOMA POPULATION IN THE COMMUNITY. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 5265-5270.	0.0	0
582	BIOPTRON LIGHT THERAPY TO DRY EYE CAUSED BY LONG - TERM TOPICALLY APPLIED ANTIGLAUCOMA DRUG WITH BENZALKONIUM - CHLORIDE. Acta Medica Medianae, 2018, 57, 109-115.	0.0	0
583	Cytotoxicity Evaluation Using in vitro System as a Criteria of Rational Choice of Tear Substitutes. Oftalmologiya, 2018, 15, 167-175.	0.2	2
586	The Tear Film: Pathological Conditions. Modeling and Simulation in Science, Engineering and Technology, 2019, , 347-371.	0.4	0
587	Research Progress of Nanoparticle Ophthalmic Drug Delivery System. Pharmacy Information, 2019, 08, 73-78.	0.1	0
588	RESEARCH OF CONSERVATIVE EFFICIENCY TREATMENT OF PATIENTS WITH DESTRUCTIVE LESION (ULCER) OF THE CORNEA. Bulletin of Problems Biology and Medicine, 2019, 1, 175.	0.0	0
590	Effect of buffer systems and preservatives in the composition of eye drops on safe and long-term treatment of patients with dry eye disease. Archive of Ukrainian Ophthalmology, 2019, 7, 37-42.	0.0	0
591	Antimicrobial Effectiveness in Eye Drops: Limited Sterility versus Reduction in Microbial Count. PDA Journal of Pharmaceutical Science and Technology, 2020, 74, 309-317.	0.3	0
592	Benzalkonium chloride antagonises aminoglycoside antibiotics and promotes evolution of resistance. EBioMedicine, 2021, 73, 103653.	2.7	29
593	Management of Ocular Surface Disease in Glaucoma: A Survey of Canadian Glaucoma Specialists. Journal of Glaucoma, 2020, 29, 1162-1172.	0.8	4
594	Effect of long-term topical antiglaucoma medication use on the ocular surface. Nigerian Medical Journal, 2020, 61, 184.	0.6	3
595	Role of Polyunsaturated Fatty Acid Derivative Flaxseeds in the Treatment of Dry Eyes- An Overview. International Journal of Current Research and Review (discontinued), 2020, 12, 35-40.	0.1	3
597	Therapy of Dry Eye Syndrome after Inflammatory Diseases of Cornea. Oftalmologiya, 2020, 17, 124-132.	0.2	0
598	Semi-fluorinated Alkane Eye Drops Reduce Signs and Symptoms of Evaporative Dry Eye Disease After Cataract Surgery. Journal of Refractive Surgery, 2020, 36, 474-480.	1.1	6



#	ARTICLE	IF	CITATIONS
599	Guidelines and recommendations for the SARS-CoV-2 health emergency. Organization of ophthalmic consultations to avoid contact between healthy and asymptomatic contagious positive subjects. <i>AboutOpen</i> , 2020, 7, 76-79.	0.2	1
600	Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. <i>Molecular Vision</i> , 2011, 17, 745-55.	1.1	22
601	Effect of contact lens material on cytotoxicity potential of multipurpose solutions using human corneal epithelial cells. <i>Molecular Vision</i> , 2011, 17, 3458-67.	1.1	18
602	Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. <i>Molecular Vision</i> , 2012, 18, 851-63.	1.1	60
603	Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. <i>Molecular Vision</i> , 2012, 18, 1803-12.	1.1	21
604	In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). <i>Transactions of the American Ophthalmological Society</i> , 2012, 110, 40-63.	1.4	41
605	Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. <i>Journal of Biochemical and Pharmacological Research</i> , 2014, 2, 175-184.	1.7	5
606	Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs. <i>Veterinary Research Forum</i> , 2012, 3, 229-32.	0.3	13
607	Comparative clinical study of conjunctival toxicities of newer generation fluoroquinolones without the influence of preservatives. <i>International Journal of Ophthalmology</i> , 2015, 8, 1220-3.	0.5	1
608	The leaves of <i>Diospyros kaki</i> exert beneficial effects on a benzalkonium chloride-induced murine dry eye model. <i>Molecular Vision</i> , 2016, 22, 284-93.	1.1	15
609	Analysis of the effects of preservative-free tafluprost on the tear proteome. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 4025-4039.	0.0	7
610	Ocular surface - a complex and vulnerable adoptive environment for topical glaucoma treatment. <i>Romanian Journal of Ophthalmology</i> , 2016, 60, 153-157.	0.4	0
611	Ocular Surface Evaluation After the Substitution of Benzalkonium Chloride Preserved Prostaglandin Eye Drops by a Preservative-free Prostaglandin Analogue. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , 2019, 8, 52-56.	0.4	8
612	Effect of topical non-steroidal anti-inflammatory drugs on healing times and complications in dogs with spontaneous chronic corneal epithelial defects. <i>Veterinary Record</i> , 2022, 190, e1118.	0.2	3
613	Difluprednate 0.05% twice a day vs Prednisolone acetate 1% four times a day for cataract postsurgical inflammation treatment. <i>Journal of Cataract and Refractive Surgery</i> , 2021, Publish Ahead of Print, .	0.7	0
614	Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results. <i>Eye and Vision (London, England)</i> , 2021, 6, 10.	1.0	10
615	Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration. <i>International Journal of Translational Medicine</i> , 2021, 1, 306-322.	0.1	4
616	Experimental Models, Induction Protocols, and Measured Parameters in Dry Eye Disease: Focusing on Practical Implications for Experimental Research. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12102.	1.8	13

#	ARTICLE	IF	CITATIONS
617	Minimizing topical medication in cataract surgery. TNOA Journal of Ophthalmic Science and Research, 2021, 59, 338.	0.0	0
618	A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1941-1946.	1.0	5
619	Trends in prescriptions for glaucoma and ocular hypertension in France between 2014 and 2019. Journal Francais D'Ophthalmologie, 2022, , .	0.2	0
620	Influence of Cytokines on Inflammatory Eye Diseases: A Citation Network Study. Journal of Clinical Medicine, 2022, 11, 661.	1.0	5
621	Physicochemical Stability of a Novel Tacrolimus Ophthalmic Formulation for the Treatment of Ophthalmic Inflammatory Diseases. Pharmaceutics, 2022, 14, 118.	2.0	7
622	Dermatological adverse effects of anti-glaucoma eye drops: a review. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 661-670.	1.3	5
623	Preparing the ocular surface for glaucoma filtration surgery: an unmet clinical need. Acta Ophthalmologica, 2022, 100, 740-751.	0.6	11
624	Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 85-91.	0.6	4
625	Application of Animal Models in Interpreting Dry Eye Disease. Frontiers in Medicine, 2022, 9, 830592.	1.2	7
626	SCD1-Fatty Acid Desaturase Inhibitor MF-438 Alleviates Latent Inflammation Induced by Preservative-Free Prostaglandin Analog Eye Drops. Journal of Inflammation Research, 2022, Volume 15, 793-806.	1.6	4
627	Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease. Pharmaceutics, 2022, 15, 201.	1.7	3
628	Role of Caspase-1 as a Biomarker of Ocular Surface Damage. American Journal of Ophthalmology, 2022, 239, 74-83.	1.7	6
629	[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. Archivos De Bronconeumologia, 2022, 58, T334-T344.	0.4	4
630	Effects of Sodium Hyaluronate Eye Drops With or Without Preservatives on Ocular Surface Bacterial Microbiota. Frontiers in Medicine, 2022, 9, 793565.	1.2	4
631	Effect of the Preservative Benzalkonium Chloride in Prostaglandin Analogues on Corneal Sensitivity. Journal of Korean Ophthalmological Society, 2022, 63, 295-300.	0.0	0
632	Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , .	1.0	2
633	Latanoprost'ın Şerhleri'ne İlişkin Yüksek Doz Göz Damlası'nın Fiziksel Özelliklerinin ve Yıllık Maliyetlerinin Karşılaştırılması. Akdeniz Medical Journal, 0, , 153-157.	0.0	0
634	Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release, 2022, 345, 334-353.	4.8	55

#	ARTICLE	IF	CITATIONS
635	Design and development of reinforced antibiotic eye drops in a community pharmacy. <i>Pharmacy &amp; Pharmacology International Journal</i> , 2021, 9, 242-247.	0.1	0
636	Disinfectants. , 2022, , 91-115.		1
637	Anti-Oxidative and Anti-Inflammatory Micelles: Break the Dry Eye Vicious Cycle. <i>Advanced Science</i> , 2022, 9, e2200435.	5.6	40
638	The Role of Atropine in Preventing Myopia Progression: An Update. <i>Pharmaceutics</i> , 2022, 14, 900.	2.0	15
641	Management Strategies for Evaporative Dry Eye Disease and Future Perspective. <i>Current Eye Research</i> , 2022, 47, 813-823.	0.7	9
642	Elevation of Tear MMP-9 Concentration as a Biomarker of Inflammation in Ocular Pathology by Antibody Microarray Immunodetection Assays. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5639.	1.8	8
643	An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival. <i>Journal of Clinical Medicine</i> , 2022, 11, 3137.	1.0	4
644	Dynamic Contrast Microscopic Optical Coherence Tomography As a Novel Method for Assessing Corneal Epithelium During Exposure to Benzalkonium Chloride. <i>Translational Vision Science and Technology</i> , 2022, 11, 28.	1.1	4
645	Glaucoma and Dry Eye Syndrome: Double Trouble. , 2023, , 147-152.		0
646	Pathophysiology of Dry Eye Disease Using Human Models. , 2023, , 69-95.		0
647	Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 3518.	1.0	3
648	A Brazilian cost-utility analysis of trabecular micro-bypass with iStent inject® for the treatment of open-angle glaucoma. <i>Revista Brasileira De Oftalmologia</i> , 2022, 81, .	0.1	1
649	Femtosecond Laser-assisted Cataract Surgery in Patients With Prior Glaucoma Surgery. <i>Journal of Glaucoma</i> , 2022, 31, 547-556.	0.8	1
650	iStent Trabecular Micro-bypass Stent Implantation Combined with Phacoemulsification for Open-Angle Glaucoma: A 2-Year Post-marketing Surveillance Study in Japan. <i>Advances in Therapy</i> , 0, , .	1.3	2
651	Nanoparticles for the treatment of glaucoma-associated neuroinflammation. <i>Eye and Vision (London, England)</i> , 2023, 18, 1-11.	1.4	3
652	Potentiometric Analysis of Benzalkonium Chloride with 3D Printed Ion-Selective Membranes. , 2022, 1, 020601.		18
653	In vitro neurotoxicity evaluation of biocidal disinfectants in a human neuron-astrocyte co-culture model. <i>Toxicology in Vitro</i> , 2022, 84, 105449.	1.1	5
654	Topical glaucoma medications - Clinical implications for the ocular surface. <i>Ocular Surface</i> , 2022, 26, 19-49.	2.2	17

#	ARTICLE	IF	CITATIONS
655	Benzalkonium chloride, a common ophthalmic preservative, compromises rat corneal cold sensitive nerve activity. <i>Ocular Surface</i> , 2022, 26, 88-96.	2.2	6
656	Cataract Surgery in Eyes with Ocular Surface Problems and Severe Dry Eye. <i>Essentials in Ophthalmology</i> , 2022, , 93-104.	0.0	0
657	Stability of voriconazole 10Âmg/mL ophthalmic solution during 90Âdays. <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2022, 7, .	0.4	0
658	Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome. , 2022, 63, 32.		9
659	Dry Eye Disease among Patients with Glaucoma under Topical Antiglaucoma Agents in a Tertiary Care Centre: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2022, 60, 800-804.	0.1	0
660	Long-term Effects of Latanoprost with Different Excipient Compositions on Intraocular Pressure, Hyperemia and Discomfort. <i>Journal of Korean Ophthalmological Society</i> , 2022, 63, 754-761.	0.0	0
661	Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study. <i>Clinical Ophthalmology</i> , 0, Volume 16, 3181-3192.	0.9	1
662	The Effect of Anti-Inflammatory Topical Ophthalmic Treatments on In Vitro Corneal Epithelial Cells. <i>Translational Vision Science and Technology</i> , 2022, 11, 16.	1.1	0
663	Benzalkonium Chloride, Even at Low Concentrations, Deteriorates Intracellular Metabolic Capacity in Human Conjunctival Fibroblasts. <i>Biomedicines</i> , 2022, 10, 2315.	1.4	3
664	Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis â€“ A review. <i>Ocular Surface</i> , 2022, 26, 211-221.	2.2	7
666	The Effect of Therapy on the Ocular Surface in Patients with Unilateral Paediatric Glaucoma. <i>Ceska A Slovenska Oftalmologie</i> , 2021, 77, 28-34.	0.1	0
667	A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants. <i>Therapeutic Advances in Ophthalmology</i> , 2022, 14, 251584142211256.	0.8	1
668	Nanotheranostic: A Versatile Approach for Eye Cancer Diagnosis and Treatment. , 2022, , 423-439.		1
669	Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience. <i>Journal of Ophthalmology</i> , 2022, 2022, 1-7.	0.6	0
670	Highlighting the Microbial Contamination of the Dropper Tip and Cap of In-Use Eye Drops, the Associated Contributory Factors, and the Risk of Infection: A Past-30-Years Literature Review. <i>Pharmaceutics</i> , 2022, 14, 2176.	2.0	4
671	Aqueous Prostaglandin Eye Drop Formulations. <i>Pharmaceutics</i> , 2022, 14, 2142.	2.0	5
672	Trends in development and quality assessment of pharmaceutical formulations - F2Î± analogues in the glaucoma treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 180, 106315.	1.9	5
673	Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma. <i>Journal of Glaucoma</i> , 2023, 32, 9-18.	0.8	9

#	ARTICLE	IF	CITATIONS
674	Pluronic®/casein micelles for ophthalmic delivery of resveratrol: In vitro, ex vivo, and in vivo tests. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122281.	2.6	9
675	Potential synergistic effect of <i>Alhagi graecorum</i> ethanolic extract with two conventional food preservatives against some foodborne pathogens. <i>Archives of Microbiology</i> , 2022, 204, .	1.0	0
676	Functionalized hydrogels in ophthalmic applications: Ocular inflammation, corneal injuries, vitreous substitutes and intravitreal injection. <i>Materials and Design</i> , 2022, 224, 111277.	3.3	9
677	Managing ocular symptoms of hay fever “ simple can be effective. <i>The Optician</i> , 2016, 2016, 142883-1.	0.0	0
678	Dry eye, cataract and refractive surgery. <i>The Optician</i> , 2017, 2017, 152186-1.	0.0	0
679	Therapeutic Potential of d-MAPPS <sup>®</sup> for Ocular Inflammatory Diseases and Regeneration of Injured Corneal and Retinal Tissue. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13528.	1.8	0
680	The case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm. <i>Current Opinion in Ophthalmology</i> , 2023, 34, 138-145.	1.3	4
681	Current progress in preservative-free topical ophthalmic formulations. <i>Journal of Drug Delivery Science and Technology</i> , 2023, 79, 103996.	1.4	1
682	Therapeutic Potential of Honey and Propolis on Ocular Disease. <i>Pharmaceutics</i> , 2022, 15, 1419.	1.7	9
683	Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6439-6451.	1.6	6
684	Therapeutic Effects of <i>Acer palmatum</i> Thumb. Leaf Extract (KIOM-2015E) on Benzalkonium Chloride-Induced Dry Eye in a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14964.	1.8	1
685	Personalized Management of Dry Eye Disease: Beyond Artificial Tears. <i>Clinical Ophthalmology</i> , 0, Volume 16, 3911-3918.	0.9	4
686	Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study. <i>PLoS ONE</i> , 2022, 17, e0277313.	1.1	2
687	Artificial Tears: A Systematic Review. <i>Clinical Optometry</i> , 0, Volume 15, 9-27.	0.4	10
688	The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction. <i>International Journal of Molecular Sciences</i> , 2023, 24, 731.	1.8	4
689	Improving Visual Comfort during Computer Gaming with Preservative-Free Hyaluronic Acid Artificial Tears Added to Ergophthalmological Measures. <i>Vision (Switzerland)</i> , 2023, 7, 5.	0.5	1
691	Recombinant Human Clusterin Seals Damage to the Ocular Surface Barrier in a Mouse Model of Ophthalmic Preservative-Induced Epitheliopathy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 981.	1.8	1
692	Discomfort During Instillation Of Antihypertensives And Ocular Surface Condition In Glaucoma Patients. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.1	1

#	ARTICLE	IF	CITATIONS
693	Devices and Treatments to Address Low Adherence in Glaucoma Patients: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 151.	1.0	9
694	The Antibiotic Kitasamycinâ€™ A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?. <i>Pharmaceutics</i> , 2023, 15, 329.	2.0	0
695	A review on drug-induced dry eye disease. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 1263-1269.	0.5	5
696	Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy. <i>Current Opinion in Ophthalmology</i> , 2023, 34, S1-S13.	1.3	2
697	Influence of BAKs on tear film lipid layer: In vitro and in silico models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2023, 186, 65-73.	2.0	2
698	Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. <i>Advanced Drug Delivery Reviews</i> , 2023, 196, 114770.	6.6	37
699	Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide. <i>Life Sciences</i> , 2023, 317, 121463.	2.0	1
700	Betaine- and L-Carnitine-Based Ionic Liquids as Solubilising and Stabilising Agents for the Formulation of Antimicrobial Eye Drops Containing Diacerein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2714.	1.8	5
701	Perturbations of the ocular surface microbiome and their effect on host immune function. <i>Current Opinion in Ophthalmology</i> , 2023, 34, 181-188.	1.3	4
703	Comprehensive management of <scp>postâ€™LASIK</scp> ectasia: From prevention to treatment. <i>Acta Ophthalmologica</i> , 2023, 101, 485-503.	0.6	3
704	Biomimetic Convex Implant for Corneal Regeneration Through 3D Printing. <i>Advanced Science</i> , 2023, 10, .	5.6	8
705	Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 309-315.	0.6	2
706	Topical Decorin Reduces Corneal Inflammation and Imparts Neuroprotection in a Mouse Model of Benzalkonium Chloride-induced Corneal Neuropathy. , 2023, 64, 20.		3
707	Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. <i>Ophthalmology and Therapy</i> , 2023, 12, 1397-1418.	1.0	18
708	Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma. <i>Eye and Vision (London, England)</i> , 2023, 10, .	1.4	2
709	Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study. <i>Clinical Ophthalmology</i> , 0, Volume 17, 735-746.	0.9	1
710	Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 0, , .	0.6	0
711	Compounded 0.01% Atropineâ€™What's in the Bottle?. <i>Eye and Contact Lens</i> , 2023, 49, 219-223.	0.8	5

#	ARTICLE	IF	CITATIONS
712	Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
713	Benzalkonium chloride-induced dry eye disease animal models: Current understanding and potential for translational research. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 1256-1262.	0.5	3
714	Ocular surface changes following vitreoretinal procedures. <i>Indian Journal of Ophthalmology</i> , 2023, 71, 1123-1126.	0.5	1
715	TFOS Lifestyle: Impact of cosmetics on the ocular surface. <i>Ocular Surface</i> , 2023, 29, 77-130.	2.2	14
716	TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface. <i>Ocular Surface</i> , 2023, 29, 331-385.	2.2	13
718	Detergent. , 2024, , 565-569.		0
723	Selective laser trabeculoplasty: physiology and effects of SLT. , 2023, , 209-216.		0
726	Eye. , 2023, , 377-403.		0
747	Use of nanotechnology in dry eye syndrome. , 2023, , 227-246.		1
753	Evolving role of plant pigments in the cosmetic industry. , 2024, , 307-319.		0
755	Challenging the "Topical Medications-First" Approach to Glaucoma: A Treatment Paradigm in Evolution. <i>Ophthalmology and Therapy</i> , 2023, 12, 2823-2839.	1.0	1
774	New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief. <i>International Ophthalmology</i> , 2024, 44, .	0.6	0